Literature DB >> 16781199

Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure.

Vassilis L Souliotis1, Meletios A Dimopoulos, Hara G Episkopou, Soterios A Kyrtopoulos, Petros P Sfikakis.   

Abstract

To investigate the molecular mechanisms of action of the nitrogen mustard melphalan in patients treated for multiple myeloma, the in vivo induction and repair of melphalan-induced DNA damage was measured in genes with different transcriptional activity (b-actin>p53>N-ras>d-globin) from leukocytes of 20 multiple myeloma patients following chemotherapeutic administration of high-dose melphalan (200mg/m(2)) and autologous blood stem cell transplantation. Heterogeneous repair was found among the studied genes. The extent of repair was always in the order: b-actin>p53>N-ras>d-globin, correlating with the gene transcriptional state. Similar findings were obtained using peripheral blood mononuclear cells (PBMC) from healthy volunteers following in vitro treatment with melphalan, indicating that these results are not malignant disease-specific. Following in vitro treatment of PBMC from healthy volunteers with alpha-amanitin, an inhibitor of RNA polymerase II that can also induce condensation of chromatin structure, a significant inhibition of the removal of melphalan-induced damage in the three active genes but not in the silent d-globin gene was found, suggesting that transcription and/or chromatin structure may play important roles in the preferential DNA repair. When the in vivo DNA damage formation and repair in multiple myeloma patients following chemotherapeutic administration of melphalan was measured in the two strands of the active genes, no strand bias was found, indicating that the global genome repair subpathway of nucleotide excision repair may play a crucial role in the repair of these adducts. These results were also confirmed in PBMC from healthy volunteers following in vitro treatment with melphalan. Using micrococcal nuclease digestion of nuclei isolated from PBMC of multiple myeloma patients before the chemotherapeutic treatment, as well as from PBMC of healthy volunteers, we probed the chromatin structure in each gene and found that the "looseness" of the chromatin structure correlated with the levels of the gene-specific repair, being again in the order: b-actin>p53>N-ras>d-globin. To conclude, the in vivo gene-specific repair of melphalan-induced damage in humans is greatly affected by the local chromatin structure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16781199     DOI: 10.1016/j.dnarep.2006.05.006

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  6 in total

1.  Quantitative PCR analysis of diepoxybutane and epihalohydrin damage to nuclear versus mitochondrial DNA.

Authors:  Frederick J Lariviere; Adam G Newman; Megan L Watts; Sharonda Q Bradley; Justin E Juskewitch; Paul G Greenwood; Julie T Millard
Journal:  Mutat Res       Date:  2009-02-21       Impact factor: 2.433

2.  Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis.

Authors:  M Gkotzamanidou; E Terpos; C Bamia; S A Kyrtopoulos; P P Sfikakis; M A Dimopoulos; V L Souliotis
Journal:  Leukemia       Date:  2013-10-03       Impact factor: 11.528

3.  DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7.

Authors:  Maria Gkotzamanidou; Evangelos Terpos; Christina Bamia; Nikhil C Munshi; Meletios A Dimopoulos; Vassilis L Souliotis
Journal:  Blood       Date:  2016-07-21       Impact factor: 22.113

4.  Nucleotide excision repair is a potential therapeutic target in multiple myeloma.

Authors:  R Szalat; M K Samur; M Fulciniti; M Lopez; P Nanjappa; A Cleynen; K Wen; S Kumar; T Perini; A S Calkins; E Reznichenko; D Chauhan; Y-T Tai; M A Shammas; K C Anderson; J-P Fermand; B Arnulf; H Avet-Loiseau; J-B Lazaro; N C Munshi
Journal:  Leukemia       Date:  2017-06-07       Impact factor: 11.528

5.  Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.

Authors:  M Gkotzamanidou; P P Sfikakis; S A Kyrtopoulos; C Bamia; M A Dimopoulos; V L Souliotis
Journal:  Br J Cancer       Date:  2014-07-22       Impact factor: 7.640

6.  Defective DNA repair and chromatin organization in patients with quiescent systemic lupus erythematosus.

Authors:  Vassilis L Souliotis; Konstantinos Vougas; Vassilis G Gorgoulis; Petros P Sfikakis
Journal:  Arthritis Res Ther       Date:  2016-08-04       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.